Next Generation CAR & T Cell Therapies is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

Jessica Sachs
Vice President, Clinical Sciences at Unum Therapeutics, USA

Profile

Jessica Sachs, M.D., is Vice President of Clinical Sciences at Unum Therapeutics Inc. (Unum), a clinical-stage oncology cell and gene therapy company based in Cambridge, MA.   She is responsible for the clinical development strategy and medical and translational oversight of the Unum portfolio, most notably ACTR (antibody-coupled T cell receptor) autologous engineered T cell clinical programs, including ongoing trials in non-Hodgkin lymphoma, multiple myeloma and Her2+ solid tumors. 

Prior to joining Unum, Dr. Sachs spent several years at Takeda/Millennium where she led multiple clinical programs in oncology and transplantation, and at Genzyme Corporation where she was responsible for post-marketing safety surveillance and risk management activities for a variety of oncology products. 

Dr. Sachs has been a faculty member of the Harvard Medical School since 2007 and is an Assistant in Pediatrics in the Division of Pediatric Hematology/Oncology at the Massachusetts General Hospital.  She completed her fellowship in pediatric hematology and oncology at the Dana Farber Cancer Institute and Children’s Hospital Boston.  She received her M.D. from Washington University in St. Louis and her B.S. from Duke University.

Agenda Sessions

  • Antibody Coupled T cell Receptor (ACTR); a novel technology that utilizes a single construct for multiple targets

    ,